Within the lung adenocarcinoma patient cohort, low MTUS1 expression was significantly associated with poorer prognoses for both DFS and CSS, in early-stage group (AJCC stages 0 and I, n = 98; p = 0.002 and p = 0.007 for DFS and CSS, respectively) and in surgical treatment-only group (n = 82; p = 0.011 and p = 0.006 for DFS and CSS, respectively). This evidence concerns the gene MTUS1 and lung adenocarcinoma.